Noxopharm Ltd. (AU:NOX) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Noxopharm Limited is set to commence the HERACLES clinical trial, having secured a specialist supplier for the production of SOF-SKN, a novel drug aimed at treating cutaneous lupus erythematosus, an autoimmune disease. The company is on track with preparations, ensuring the drug meets high quality standards and regulatory requirements for the early 2025 first-in-human trials. This development is a part of Noxopharm’s broader efforts in the growing immunology market, targeting conditions that affect millions globally.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.